PROMO!
First order? Get 10% OFF with this code: 1storder
hMG (human menopausal gonadotropin) is a glycoprotein gonadotropin preparation containing follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity, derived from human postmenopausal urine.
Human Menopausal Gonadotropin (hMG), is also known as menotropin, and is a complex gonadotropin preparation containing follicle-stimulating hormone (FSH) and luteinising hormone (LH) bioactivity. Unlike short synthetic research peptides, hMG is composed of heterodimeric glycoprotein hormones and should therefore be characterized as a gonadotropin preparation rather than a single peptide.
Laboratory research involving hMG can focus on its protein composition, gonadotropin-receptor interactions, glycoprotein characteristics and associated molecular signaling systems. Compositional studies have identified FSH, LH and, in some preparations, human chorionic gonadotropin (hCG) alongside other protein components, meaning the precise composition can depend on the preparation and purification process.
Human Menopausal Gonadotropin (hMG/menotropin) is a complex glycoprotein preparation, rather than a single synthetic peptide with one defined molecular mass or sequence. Its principal gonadotropin components provide FSH and LH-associated molecular activity, although the precise protein composition can vary according to the preparation and purification process. Analytical studies have also identified hCG and other protein components in some highly purified hMG preparations.
The individual gonadotropins are heterodimeric glycoproteins composed of a common α-subunit associated non-covalently with a hormone-specific β-subunit. Their structures contain multiple disulfide bonds and carbohydrate chains, with glycosylation contributing substantially to molecular heterogeneity. FSH, for example, contains N-linked glycans on both its α- and β-subunits.
Human Menopausal Gonadotropin (hMG/menotropin) is investigated as a multi-component gonadotropin preparation containing FSH and LH-associated molecular activity. Its mechanism is therefore better described through the receptor interactions of its individual glycoprotein components rather than as the action of a single peptide.
Gonadotropin Receptor Binding
LH-associated components interact with the luteinizing hormone/choriogonadotropin receptor (LHCGR), whereas the FSH component interacts with the follicle-stimulating hormone receptor (FSHR). Both receptors offer well-established experimental settings for examining glycoprotein hormone–receptor recognition and are members of the G-protein-coupled receptor (GPCR) family.
cAMP-Associated Signaling
FSHR and LHCGR activation is associated with Gαs signalling, which stimulates adenylyl cyclase and increases levels of intracellular cyclic AMP (cAMP). This activates protein kinase A (PKA) and related downstream signaling processes. Because changes in cAMP and PKA activity can be measured experimentally, they provide useful biochemical markers for studying gonadotropin receptor signaling under controlled laboratory conditions.
Additional Signaling Pathways
Signaling involving β-arrestins, ERK/MAPK, intracellular Ca2+, and other receptor-associated pathways has also been uncovered by gonadotropin receptor studies. Experimental circumstances, glycoprotein composition, and receptor expression can all affect the relative signaling profile.
Instead of interpreting hMG as a single chemically uniform ligand, its molecular activity should be evaluated in conjunction with its batch-specific FSH/LH-associated composition and analytical features because it is a heterogeneous glycoprotein preparation.
This summary reflects findings reported in published preclinical and in vitro research. The original studies supporting this information are listed in the references.
FSH, LH, and hCG-associated components of HMG have been studied utilizing compositional and proteomic methods. Batch- and preparation-specific characterisation is especially important because studies have shown that the exact molecular composition might vary between preparations.
Examining interactions with the follicle-stimulating hormone receptor (FSHR) is made possible by the FSH-associated part of HMG. Receptor binding, activation, and related intracellular signaling, including cAMP-dependent pathways, can all be studied.
The luteinizing hormone/choriogonadotropin receptor (LHCGR) can be examined in relation with LH and hCG-associated components. Ligand recognition and variations in receptor-associated signaling between LH and hCG have been investigated at the molecular level.
Cell-based studies of HMG preparations have measured molecular endpoints including cAMP formation, intracellular Ca²⁺ signaling and β-arrestin recruitment. These provide experimental markers for comparing receptor-associated signaling between different gonadotropin preparations.
Research can also concentrate on subunit composition and glycosylation because the gonadotropin components of HMG are heterodimeric glycoproteins. Molecular heterogeneity and receptor interactions are related to variations in glycan structures and glycoforms.
Analytical and cell-based techniques can be used to compare the molecular signaling pathways, protein composition, and FSH-to-LH/hCG-associated activity of different HMG preparations. Published in-vitro studies have demonstrated quantifiable compositional and early-signaling differences between commercially made hMG products.
Instead of treating Human Menopausal Gonadotropin (hMG/menotropin) as a single defined peptide, analytical verification should take into consideration its multi-component glycoprotein composition. Protein composition, molecular heterogeneity, and the existence of extra protein species can be evaluated using methods like gel electrophoresis and RP-HPLC. RP-HPLC and proteomic techniques have been specifically applied to hMG preparations in published compositional investigations.
For more detailed molecular characterisation, mass spectrometry and LC-MS/MS can identify gonadotropin components and provide information on protein identity, glycoforms and post-translational modifications. SDS-PAGE and two-dimensional electrophoresis have also been combined with mass spectrometry to evaluate hMG preparations.
For lyophilized HMG preparations, refrigerated storage at 2–8°C, protected from light and moisture, is commonly specified.
The material should remain in its original sealed container, and unnecessary temperature fluctuations should be avoided. Because storage requirements can vary between HMG preparations, the batch-specific Certificate of Analysis and supporting documentation should be consulted for the verified conditions applicable to the supplied research material.
HMG (Human Menopausal Gonadotropin/menotropin) is more accurately described as a multi-component glycoprotein preparation, rather than a single peptide. Its principal gonadotropin components are structurally complex glycoprotein hormones composed of protein subunits with carbohydrate modifications.
HMG preparations contain gonadotropin components providing FSH and LH-associated activity. Analytical studies of highly purified HMG have identified FSH, LH and hCG, together with additional protein species whose abundance can vary according to the preparation and purification process.
HMG is not a single chemically uniform molecule. Differences in source material, purification, standardization, and manufacturing processes can result in variation in gonadotropin composition, glycoforms, and additional protein species between preparations.
The gonadotropins present in HMG are glycoproteins, meaning carbohydrate structures form part of their molecular characteristics. Glycosylation contributes to molecular heterogeneity, so techniques that evaluate glycan patterns can provide additional information about the composition and identity of an HMG preparation.
The follicle-stimulating hormone receptor (FSHR) is a G protein-coupled receptor that specifically recognizes FSH. In laboratory research, FSHR provides a defined molecular system for studying gonadotropin–receptor binding and associated intracellular signalling.
The LHCGR is a G-protein-coupled receptor capable of recognising both LH and hCG. It provides an experimental receptor system for investigating ligand recognition, receptor activation and molecular signalling associated with LH/hCG-containing preparations. Cell-based HMG research has examined LHCGR alongside FSHR.
Yes. Because HMG is a complex glycoprotein preparation, composition, isoform patterns, glycosylation, and other analytical characteristics can vary between preparations or batches. This makes batch-specific analytical documentation particularly important when characterizing research material.
HMG can be characterized using complementary methods, including RP-HPLC, SDS-PAGE, two-dimensional gel electrophoresis, and mass spectrometry. More detailed techniques such as LC-MS/MS, peptide mapping and glycosylation analysis can provide additional information on protein identity, impurities, isoforms and glycan heterogeneity.
Human menopausal gonadotropin (HMG/menotropin) is intended solely for laboratory research and scientific study. It is not intended for human or animal consumption, administration, veterinary use, clinical use or therapeutic use. This material is not intended to diagnose, treat, cure, or prevent any disease or condition.
